Tech Company Financing Transactions
Immunitas Therapeutics Funding Round
Immunitas Therapeutics, based in Waltham, secured $39 million in investment from Bayer, Novartis Venture Fund and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
11/22/2019
Transaction Type
Venture Equity
Amount
$39,000,000
Round
Series A
Investors
Proceeds Purpose
The company plans to use this funding to advance its first programs, monoclonal antibody therapeutics with single agent activity in preclinical models of oncology, to clinical studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
830 Winter St. 2nd floor
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Overview
Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Goldberg
Co-Founder
Lea Hachigian
Co-Founder
Christopher Westphal
VP - Bus. Development
Amanda Wagner
Browse more venture capital transactions:
Prev: 11/22/2019: Give InKind venture capital transaction
Next: 11/22/2019: Quantivate venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs